Second-Quarter Consumer Health Results Bring J&J Relief From Year-Ago Sales Plummet
Segment's Results Likely Better Than Remainder Of 2021, J&J And Analyst Say
Executive Summary
In first of what could be similar April-June earnings results from major consumer health firms, J&J reports 9.2% operational growth to $3.74bn in sales. Worldwide consumer health chief Thibaut Mongon touts segment’s results and outlook but says similar growth in second half isn’t assured.
You may also be interested in...
J&J Recall Of Benzene-Tainted Sunscreens Lends Weight To Valisure Claims, Triggers Class Action
J&J says the recall decision was made out of an abundance of caution, maintaining that daily exposure to benzene at levels detected in J&J sunscreen products “would not be expected to cause adverse health consequences.”
J&J Appeal Of $2bn Talcum Powder Judgment Denied By US Supreme Court
The Supreme Court said on 1 June that it would not review a $2bn verdict in Missouri for 22 women who alleged links between ovarian cancer and asbestos-tainted talc in Johnson’s Baby Powder. J&J believes the US' top court passed on an "extraordinary opportunity" that "leaves unresolved significant legal questions that state and federal courts will continue to face."
Valisure’s Benzene Testing Finds Problems With OTC Sunscreens, Cosmetic Sun Care Products
Independent lab's analysis found benzene levels at “up to three times the conditionally restricted FDA concentration limit of 2 ppm" in 10 Neutrogena sunscreen formulations.